For years, researchers have suspected that a hormone called relaxin could be an effective treatment for certain ...

Discover how therapeutic peptides act as biological messengers to treat disease, improve metabolism, and enhance immune ...

The Fc fusion protein market thrives on innovative therapies targeting oncological and genetic disorders. Key opportunities lie in developing stable and soluble treatments, partnering with research ...

The company seeks to leverage the benefits of estrogen signaling to prevent age-related diseases and improve the “healthspan" ...

NAEs are lipid-based endogenous signaling molecules that are produced by combining long-chain fatty acids with ethanolamine. Collectively, NAEs include both endocannabinoids and structurally related ...

Structure Therapeutics’ aleniglipron Phase 2 shows ~16% placebo-adjusted weight loss; a best-in-class oral GLP-1 with strong ...

Microglia (immune cells) and the RANK protein are essential for triggering puberty and maintaining fertility in the brain.

With India’s semaglutide patent expiring on 20 March, about 50 branded generics are expected to enter the market.

Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter ended December 31, 2025.

The therapeutic landscape for cutaneous T-cell lymphoma (CTCL) is undergoing a significant shift with the emergence of ...

Epigenetic programming from prolonged undernutrition and terror can persist 3–4 generations, plausibly contributing to ...

Detailed price information for Voyager Therapeut (VYGR-Q) from The Globe and Mail including charting and trades.